Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Accounts Payables (2016 - 2026)

Intellia Therapeutics has reported Accounts Payables over the past 12 years, most recently at $18.8 million for Q1 2026.

  • Quarterly Accounts Payables rose 52.05% to $18.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $18.8 million through Mar 2026, up 52.05% year-over-year, with the annual reading at $20.3 million for FY2025, 38.82% up from the prior year.
  • Accounts Payables was $18.8 million for Q1 2026 at Intellia Therapeutics, down from $20.3 million in the prior quarter.
  • Over five years, Accounts Payables peaked at $20.3 million in Q4 2025 and troughed at $3.6 million in Q3 2023.
  • The 5-year median for Accounts Payables is $11.6 million (2023), against an average of $11.3 million.
  • Year-over-year, Accounts Payables skyrocketed 269.97% in 2024 and then tumbled 47.91% in 2025.
  • A 5-year view of Accounts Payables shows it stood at $5.2 million in 2022, then skyrocketed by 44.59% to $7.5 million in 2023, then soared by 95.77% to $14.6 million in 2024, then surged by 38.82% to $20.3 million in 2025, then dropped by 7.17% to $18.8 million in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Accounts Payables are $18.8 million (Q1 2026), $20.3 million (Q4 2025), and $13.3 million (Q3 2025).